Posted by Michael Wonder on 02 Nov 2018
Drug Utilisation Sub-Committee outcome statement - September 2018
2 November 2018 - The outcome statement from the September 2018 Drug Utilisation Sub Committee meeting is now available.
The Drug Utilisation Sub-Committee (DUSC) of the PBAC held its 94th meeting on the 27th and 28th of September 2018.
DUSC reviewed the utilisation of the following technologies:
- Febuxostat for hyperuricaemia
- Direct acting anti-viral medicines for hepatitis C virus infection
- Ruxolitinib phosphate for myelofibrosis
- Bevacizumab for ovarian cancer
